<DOC>
	<DOCNO>NCT01869088</DOCNO>
	<brief_summary>The purpose study determine TACE plus Recombinant Human Adenovirus Type 5 Injection improve outcome patient advance hepatocellular carcinoma ( HCC ) amenable surgery local ablative therapy .</brief_summary>
	<brief_title>TACE Plus Recombinant Human Adenovirus Hepatocellular Carcinoma</brief_title>
	<detailed_description>Transarterial chemoembolization ( TACE ) currently one mainstay palliative treatment worldwide patient unresectable Hepatocellular Carcinoma ( HCC ) .However , long term outcome generally poor HCC patient treat TACE . Recombinant Human Adenovirus Type 5 , E1B gene delete adenovirus , know significant antitumor activity . In addition , local injection recombinant human adenovirus type 5 enhance effect antitumor therapy ( chemotherapy radiotherapy ) . The hypothesis patient unresectable HCC may benefit recombinant human adenovirus type 5 combination TACE .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<criteria>Patients newly diagnose HCC accord European Association Study Liver criterion . BCLC stage A B ChildPugh class A B ( ChildPugh score 7 ) ECOG performance status 0 Patients must least one tumor lesion meet follow criterion : The lesion accurately measure least one dimension accord RECIST criteria The lesion previously treat surgery , radiation therapy , radiofrequency ablation , percutaneous ethanol acetic acid injection , cryoablation . Patients receive previous local therapy treatment ( RFA , PEI , cryoablation , surgery , resection ) nontarget lesion eligible Local therapy must complete least 4 week prior baseline scan . Haematology : Absolute neutrophil count ( ANC ) &gt; 1 x 109/L , Platelet count &gt; 40 x 109/L , Haemoglobin &gt; 9 g/dL ( may transfuse maintain exceed level ) Prothrombin time international normalized ratio &lt; 1.5 Biochemistry : Total bilirubin &lt; 2 mg/dL Serum creatinine &lt; 1.5 x upper limit normal Ability understand protocol agree sign write informed consent document Tumor factor Presence extrahepatic metastasis Predominantly infiltrative lesion Diffuse tumor morphology extensive lesion involve lobe . Vascular complication Hepatic artery thrombosis , Partial complete thrombosis main portal vein , Tumor invasion portal branch contralateral lobe , Hepatic vein tumor thrombus , Significant arterioportal shunt amenable shunt blockage Liver function Advanced liver disease : ascites , hepatic encephalopathy Patients clinically significant gastrointestinal bleeding within 30 day prior study entry . Others Renal failure require hemo peritoneal dialysis Pregnant lactate woman . Active sepsis bleeding . Hypersensitivity intravenous contrast agent . The patient receive prior treatment HCC target lesion . History cardiac disease Congestive heart failure &gt; NYHA class 2 ; active coronary artery disease Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin . Hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management . Serious nonhealing wound ( include wound heal secondary intention ) , acute nonhealing ulcer , bone fracture within 3 month . The patient , opinion investigator , unable / unwilling comply treatment study instruction . Substance abuse ( current ) , psychological , social condition may interfere patient 's participation study evaluation study result . Any active clinically serious infection ( &gt; grade 2 NCICTCAE ver 3.0 ) HIV infection AIDSrelated illness serious acute chronic illness ( base medical history )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>TACE</keyword>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>overall survival</keyword>
	<keyword>Recombinant Human Adenovirus Type 5 Injection</keyword>
</DOC>